Venlafaxine (HCl)

Venlafaxine (HCl) is oral antidepressant with novel structure. Venlafaxine (HCl) is designated as (+/-)-1-[alpha-[(dimethylamino) methyl]-p-methoxybenzyl] cyclohexanol hydrochloride. Venlafaxine (HCl) is chemically unrelated to other available antidepressant agents, but actions are similar to tricyclic antidepressants (e.g. amitriptyline). It inhibits the neuronal reuptake of the neurotransmitters, noradrenaline and serotonin but does not exhibit anticholinergic effects. Therefore less likely to cause cardiac effects or convulsions during therapy or in case of overdosage.

Venlafaxine (HCl) is primarily indicated in conditions like Major Depressive disorder, Generalized Anxiety Disorder, Social Anxiety Disorder, Panic disorder, Hot Flashes Due to Hormonal Chemotherapy (Off-label), Post traumatic Stress Disorder (Off-label), Attention Deficit Disorder (Off-label), Neuropathic pain.

Venlafaxine (HCl)

The severe or irreversible adverse effects of Venlafaxine (HCl), which give rise to further complications include Hypertension, Palpitation, Migraine. The symptomatic adverse reactions produced by Venlafaxine (HCl) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Flatulence, Dizziness, Headache, Vomiting, Anorexia, Abdominal pain, Dry mouth, Weight gain/Weight loss, Increased intracranial pressure, Neck pain, Flu like syndrome, Insomnia, Diaphoresis, Nervousness, Anorgasmia, Abnormal Vision, Impotence, Paresthesia, Tremor, Vasodilation, Yawning.

Venlafaxine should be used only if clearly needed during pregnancy. It should be used with caution in patients with pre-existing kidney disease, liver disease, heart disease, high blood pressure or if have any allergy. It should be used with caution in elderly persons because they are more sensitive to the effects of this medication.

If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

75 mg (75 (75)) As recommended. PO — Usually in 2-3 divided doses. Dose may be increased to 150 mg after several weeks if necessary.

( ) — Not recommended in this age group

( ) — Not recommended in this age group

Venlafaxine (HCl) is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementCimetidine (HCl)DiphenhydramineParegoricCentral nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.ModerateDuring concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Ambulatory patients should be made aware of the possibility of additive CNS effects (e.g., drowsiness, dizziness, lightheadedness, confusion) and counseled to avoid activities requiring mental alertness until they know how these agents affect them. Patients should also be advised to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.VORICONAZOLEVoriconazole may increase the serum concentration of venlafaxine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects Vortioxetineincreases toxicity of vortioxetineuse alternative These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Tab, Caps Store in a well closed container, Below 40°C. Protect from Sunlight and Heat.